N4 Pharma upbeat on recent Nuvec developments
(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
Read moreMon, 29th Oct 2018 10:51
(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA research efforts on Thursday.
Read more(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:
Read more(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.
Read more(Alliance News) - N4 Pharma PLC on Thursday said it bought a controlling interest in Nanogenics Ltd, a company with a lipid and peptide-based delivery system called Liptide.
Read more(Alliance News) - N4 Pharma PLC on Tuesday said its business outreach is ongoing as it continued to work on getting Nuvec, its delivery system for vaccines and cancer treatment, into clinic.
Read more(Alliance News) - Stock prices in London were largely higher at midday on Tuesday, with stimulus talks in China helping lift the mood, as attention turns to the US Federal Reserve which begins its two-day monetary policy meeting later.
Read more(Alliance News) - N4 Pharma PLC on Tuesday saw its shares rise, as it celebrated a patent grant for Nuvec in the US.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read moreN4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Says it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council. Professor Chengzhong Yu, senior group leader at the Australian Institute for Bioengineering & Nanotechnology, has been awarded an AUD402,115 grant - around GBP211,366 - to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid therapies.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.
Read more